Expression of PD-L1 through evolution phase from pre-invasive to invasive lung adenocarcinoma

被引:9
作者
Zhou, Jiebai [1 ]
Lin, Huo [2 ]
Ni, Zheng [3 ]
Luo, Rongkui [3 ]
Yang, Dawei [1 ]
Feng, Mingxiang [4 ]
Zhang, Yong [1 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Dept Pulm & Crit Care Med, Shanghai, Peoples R China
[2] Shishi Cty Hosp, Dept Pulm & Crit Care Med, Shishi, Fujian, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Dept Pathol, Shanghai, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Lung cancer; Early-stage; PD-L1; expression; Adenocarcinoma evolution; CANCER; ANTIBODIES; PROGNOSIS; SPREAD;
D O I
10.1186/s12890-023-02310-0
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
BackgroundThis study evaluated programmed cell death-ligand 1 (PD-L1) expression from pre-invasive adenocarcinoma to invasive lung adenocarcinoma, aimed to investigate the potential association of PD-L1 pathway with lung adenocarcinoma early evolution.MethodsWe evaluated PD-L1 expression in 1123 resected lung specimens of adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma (IAC) of stage IA1-IA3. PD-L1 expression was defined based on the proportion of stained tumor cells using the tumor proportion score: < 1% (negative), >= 1% (positive) and >= 50% (strongly positive). Correlations between PD-L1 expression and T stage, pathological subtype, adenocarcinoma grade, spread through air space (STAS), vascular invasion, lymphatic invasion and driven genes were analyzed.ResultsThere was almost no PD-L1 expression in AIS or MIA. However, PD-L1 expression was correlated with invasiveness of lung adenocarcinoma. The percentages of PD-L1 positive in IA1-IA3 were 7.22%, 11.29%, and 14.20%, respectively. The strongly positive rates of PD-L1 were 0.38%, 1.64%, and 3.70% in IA1-IA3, respectively. PD-L1 expression and positive rate were also associated with poor pathological subtype and poor biological behavior, such as adenocarcinoma Grade 3, micropapillary or solid dominant subtype, STAS and vascular invasion. Finally, PD-L1 positive rate seems also corrected with driven gene ALK, ROS-1 and KRAS.ConclusionsPD-L1 expression was positively correlated with the emergence of invasiveness and poor pathological subtype or biological behavior of early-stage lung adenocarcinoma. PD-L1 pathway may be involved in the early evolution of lung adenocarcinoma from AIS to IAC.
引用
收藏
页数:9
相关论文
共 27 条
  • [1] Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma
    Altorki, Nasser K.
    Borczuk, Alain C.
    Harrison, Sebron
    Groner, Lauren K.
    Bhinder, Bhavneet
    Mittal, Vivek
    Elemento, Olivier
    McGraw, Timothy E.
    [J]. CELL REPORTS, 2022, 39 (01):
  • [2] Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage IA non-small cell lung cancer
    Duan, Jin
    Lv, Guoli
    Zhu, Nanye
    Chen, Xin
    Shao, Yang
    Liu, Yong
    Zhao, Wei
    Shi, Yunfei
    [J]. THORACIC CANCER, 2022, 13 (07) : 947 - 955
  • [3] PD-L1 Predicts Poor Prognosis in Surgically Resected Limited Stage Small-Cell Lung Cancer
    Fu, Xiao
    Liu, Zhiyan
    Xiang, Luochengling
    Liu, Mengjie
    Zheng, Xiaoqiang
    Wang, Jingjing
    Liu, Na
    Gao, Huan
    Jiang, Aimin
    Yang, Yujuan
    Liang, Xuan
    Ruan, Zhiping
    Tian, Tao
    Yao, Yu
    [J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 10939 - 10948
  • [4] PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
    Gandini, Sara
    Massi, Daniela
    Mandala, Mario
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 100 : 88 - 98
  • [5] Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
    Herbst, Roy S.
    Giaccone, Giuseppe
    de Marinis, Filippo
    Reinmuth, Niels
    Vergnenegre, Alain
    Barrios, Carlos H.
    Morise, Masahiro
    Felip, Enriqueta
    Andric, Zoran
    Geater, Sarayut
    Ozguroglu, Mustafa
    Zou, Wei
    Sandler, Alan
    Enquist, Ida
    Komatsubara, Kimberly
    Deng, Yu
    Kuriki, Hiroshi
    Wen, Xiaohui
    McCleland, Mark
    Mocci, Simonetta
    Jassem, Jacek
    Spigel, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (14) : 1328 - 1339
  • [6] Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms
    Koppel, Christina
    Schwellenbach, Helena
    Zielinski, Dirk
    Eckstein, Sina
    Martin-Ortega, Mercedes
    D'Arrigo, Corrado
    Schildhaus, Hans-Ulrich
    Rueschoff, Josef
    Jasani, Bharat
    [J]. MODERN PATHOLOGY, 2018, 31 (11) : 1630 - 1644
  • [7] Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types
    Krigsfeld, Gabriel S.
    Prince, Emily A.
    Pratt, James
    Chizhevsky, Vladislav
    Ragheb, Josette William
    Novotny, James, Jr.
    Huron, David
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2020, 73 (10) : 656 - 664
  • [8] Solid histological component of adenocarcinoma might play an important role in PD-L1 expression of lung adenocarcinoma
    Miyazawa, Tomoyuki
    Morikawa, Kei
    Otsubo, Kanji
    Sakai, Hiroki
    Kimura, Hiroyuki
    Chosokabe, Motohiro
    Furuya, Naoki
    Marushima, Hideki
    Kojima, Koji
    Mineshita, Masamichi
    Koike, Junki
    Saji, Hisashi
    [J]. THORACIC CANCER, 2022, 13 (01) : 24 - 30
  • [9] PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes
    Miyazawa, Tomoyuki
    Marushima, Hideki
    Saji, Hisashi
    Kojima, Koji
    Hoshikawa, Masahiro
    Takagi, Masayuki
    Nakamura, Haruhiko
    [J]. ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY, 2019, 25 (01) : 1 - 9
  • [10] Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer
    Montero, M. Angeles
    Aricak, Ozan
    Kis, Lorand
    Yoshikawa, Akira
    De Petris, Luigi
    Grundberg, Oscar
    Pham, Hoa H. N.
    Roden, Anja C.
    Fukuoka, Junya
    Attanoos, Richard
    Guijarro, Ricardo
    Alarcon, Felix
    Lindstrom, Kati
    Ortiz-Villalon, Cristian
    [J]. ANNALS OF DIAGNOSTIC PATHOLOGY, 2021, 51